Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.22624
Abstract: KIT kinase V559D mutation is the most prevalent primary gain-of-function mutation in Gastrointestinal Stromal Tumors (GISTs). Here we reported a highly selective KIT V559D inhibitor CHMFL-KIT-031, which displayed about 10-20 fold selectivity over KIT wt… read more here.
Keywords: kit kinase; v559d; gastrointestinal stromal; stromal tumors ... See more keywords
Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo.2016.09.15
Abstract: The therapeutic implications of the genomic alterations seen within the drivers of gastrointestinal stromal tumors (GIST) are among the best understood in all of solid tumors. Sequencing of cKIT and PDGFRα should be considered standard… read more here.
Keywords: management; gastrointestinal stromal; stromal tumors; gist ... See more keywords
Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14122831
Abstract: Simple Summary Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GISTs mainly develop in older adults, and the median age of diagnosis is 60–65 years. The incidence of GISTs… read more here.
Keywords: stromal tumors; molecular abnormalities; tumors gists; gists young ... See more keywords